| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -19,177 | -17,706 | -20,051 | -30,089 |
| Depreciation and amortization expense | 590 | -397 | 950 | 1,836 |
| Amortization of debt issuance cost | 377 | 1,362 | NaN | NaN |
| Non-cash interest expense | 25 | 25 | 25 | 50 |
| Non-cash lease expense | 323 | 326 | 324 | 620 |
| Non-cash expense from collaborative arrangements, net | 698 | -222 | 918 | 1,766 |
| Stock-based compensation expense | 3,398 | 2,002 | 1,975 | 3,730 |
| Other | -10 | -1,010 | -9 | -20 |
| Prepaid expenses and other current assets | 927 | 694 | -795 | 2,708 |
| Accounts payable and accrued expenses | -5,398 | 1,206 | 3,289 | -1,184 |
| Other non-current liabilities | NaN | NaN | 90 | NaN |
| Lease obligations | -317 | -631 | NaN | -596 |
| Net cash used in operating activities | -21,794 | -13,961 | -12,916 | -30,087 |
| Purchases of property and equipment | 6 | 35 | 91 | 59 |
| Payment of security deposits | NaN | 0 | -5 | 131 |
| Payment of long term deposits | 0 | NaN | NaN | NaN |
| Net cash used in investing activities | -6 | -35 | -86 | -190 |
| Proceeds from issuance of common stock | 22,500 | 19,854 | NaN | NaN |
| Proceeds from issuance of common stock upon exercise of warrants | 15,000 | NaN | NaN | NaN |
| Proceeds from exercise of equity awards, net | 88 | NaN | NaN | NaN |
| Payment of equity issuance costs | 1,779 | 1,342 | NaN | 184 |
| Proceeds from issuance of debt | NaN | 0 | NaN | NaN |
| Issuance of common stock and warrants, net | NaN | NaN | 18,326 | NaN |
| Payments of debt issuance costs | NaN | 0 | NaN | NaN |
| Payment of warrant issuance costs | 825 | NaN | NaN | NaN |
| Payment of eb-5 loan | 0 | 0 | 0 | 1,000 |
| Net cash provided by (used in) financing activities | 34,984 | 2 | 18,510 | -1,184 |
| Effect of changes in exchange rate on cash and restricted cash | 102 | 3 | 46 | -36 |
| Net increase (decrease) in cash and restricted cash | 13,286 | -13,991 | 5,554 | -31,497 |
| Cash and restricted cash at beginning of period | 18,887 | 32,879 | 58,821 | NaN |
| Cash and restricted cash at end of period | 32,173 | 18,887 | 32,879 | NaN |
Ocugen, Inc. (OCGN)
Ocugen, Inc. (OCGN)